IMMU-38. PRECLINICAL VALIDATION AND MANUFACTURE OF IL-8 RECEPTOR-MODIFIED CD70 CAR T CELLS FOR CLINICAL TRIAL

BACKGROUND: Chimeric antigen receptor (CAR) modified T cell therapy is a promising treatment strategy for cancer therapy. We developed IL-8 receptor-linked CD70CAR (8R-70CAR), aiming to enhance T-cell intratumoral trafficking and persistence, guided by IL-8-secreting tumors. The preclinical results...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Jin, Linchun, Tao, Haipeng, Na, Meng, Karachi, Aida, Mendez-Gomez, Hector, Weidert, Frances, Hou, Alicia, Sayour, Elias, Mitchell, Duane, Huang, Jianping
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651229/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.468
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires